- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03126266
Re-Irradiation of Progressive or Recurrent DIPG
July 31, 2023 updated by: University of Calgary
ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
This is a single-arm, non-randomized study of re-irradiation of diffuse intrinsic pontine glioma (DIPG)
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Study therapy will consist of radiation therapy (RT) given over 17 treatment days (for 30.6 Gy in fractions of 1.8 Gy) or 20 treatment days (for 36 Gy in 1.8 Gy fractions), depending on the time from completion of the first course of RT.
Treatment days will generally be weekdays, not including statutory holidays.
Study Type
Interventional
Enrollment (Estimated)
27
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lucie Lafay-Cousin, MD
- Phone Number: 1 403 955 2554
- Email: lucie.lafay-cousin@ahs.ca
Study Contact Backup
- Name: Eric Bouffet, MD
- Phone Number: 1 416 813 7457
- Email: eric.bouffet@sickkids.ca
Study Locations
-
-
New South Wales
-
Westmead, New South Wales, Australia
- Recruiting
- The Children's Hospital at Westmead
-
Contact:
- Dinisha Govender, MD
-
-
Queensland
-
Brisbane, Queensland, Australia
- Recruiting
- Queensland Children's Hospital
-
Contact:
- Timothy Hassall, MD
-
-
Victoria
-
Clayton, Victoria, Australia
- Recruiting
- Monash Children's Hospital
-
Contact:
- Paul Wood, MD
-
Parkville, Victoria, Australia
- Recruiting
- Royal Children's Hospital
-
Contact:
- Jordan Hansford, MD
-
-
Western Australia
-
Perth, Western Australia, Australia
- Recruiting
- Perth Children's Hospital
-
Contact:
- Nick Gottardo, MD
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Recruiting
- Alberta Children's Hospital
-
Contact:
- Lucie Lafay-Cousin, MD
- Phone Number: 403 955 2554
- Email: lucie.lafay-cousin@ahs.ca
-
Contact:
- Tao Wang, MSc
- Email: Tao.Wang@ahs.ca
-
Edmonton, Alberta, Canada
- Recruiting
- Stollery Children's Hospital
-
Contact:
- Susan Chafe, MD
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- Recruiting
- BC Children's Hospital
-
Contact:
- Juliette Hukin, MD
-
-
Newfoundland and Labrador
-
Saint John's, Newfoundland and Labrador, Canada
- Recruiting
- Janeway Child Health Centre
-
Contact:
- Lynette Bowes, MD
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada
- Recruiting
- IWK Health Centre
-
Contact:
- Craig Erker, MD
-
-
Ontario
-
Hamilton, Ontario, Canada
- Recruiting
- McMaster Children's Hospital
-
Contact:
- Adam Fleming, MD
-
London, Ontario, Canada
- Recruiting
- Children's Hospital at London Health Sciences Centre
-
Contact:
- Shayna Zelcer, MD
-
Ottawa, Ontario, Canada
- Recruiting
- Children's Hospital of Eastern Ontario
-
Contact:
- Donna Johnston, MD
-
Toronto, Ontario, Canada
- Recruiting
- The Hospital for Sick Children
-
Contact:
- Ute Bartels, MD
-
-
Quebec
-
Laval, Quebec, Canada
- Recruiting
- CHU de Quebec-Universite Laval
-
Contact:
- Samuele Renzi, MD
-
Montreal, Quebec, Canada
- Recruiting
- Montreal Children's Hospital
-
Contact:
- Sonia Skamene, MD
-
Montréal, Quebec, Canada
- Recruiting
- Centre Hospitalier Universitaire Sainte-Justine
-
Contact:
- Sebastian Perreault, MD
-
-
-
-
-
Auckland, New Zealand
- Recruiting
- Starship Hospital
-
Contact:
- Karen Tsui, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
All of these criteria must be met for a patient to be eligible for this study:
- Each site may accept a patient on study of any age that they have permission to treat and follow on study per their institutional policy.
- The patient has no evidence of metastases on cranial or spinal MR imaging
- The patient has received RT in the past, given to a total cumulative dose of <60 Gy; prior radiation using opposed lateral fields, conformal 3-D fields, IMRT or using protons is acceptable
- At least 180 days have elapsed from the last day of primary RT for DIPG
- The patient has recovered from all acute and subacute toxicities of prior RT and of chemotherapy, if chemotherapy was utilized in the past
- The patient has been off all anti-tumour therapy for at least 14 days
- The patient has a Lansky score of 40% or higher
- The patient has a life expectancy anticipated to be at least 8 weeks with treatment using re-irradiation, with or without dexamethasone
- The patient has no uncontrolled medical condition (e.g., seizures, diabetes, infection) that would interfere with the delivery of rRT
- The patient agrees to not enroll on any other clinical trial of an anti-tumour intervention
- The patient agrees to report and have recorded the use of all medications taken during ReRAD therapy, from the time of diagnosis of progression or recurrence, then through and after completion of, ReRAD therapy; this includes the use of complementary, alternative and dietary therapies
- The patient is treated at a site where the study is approved by the local ethics board
- Males and females of child-bearing potential must agree to use effective birth control measures during rRT
- Consent, and, if applicable, assent, has been obtained according to institutional standards
Exclusion Criteria:
If the patient fulfills any of these criteria, then he or she will not be eligible for the study:
- Females who are pregnant, due to risks from rRT on the developing fetus.
- Any patient with a condition that prohibits the planned delivery of rRT as prescribed in this study.
- Patients who are receiving any other clinical trial of an anti-tumour intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients receiving re-irradiation
Patients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
|
if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
second progression-free survival
Time Frame: up to 18 months from the start of re-irradiation
|
length of time from start of re-irradiation to subsequent progression of disease
|
up to 18 months from the start of re-irradiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival
Time Frame: up to three years from initial diagnosis of DIPG
|
time from initial diagnosis of DIPG to death following re-irradiation
|
up to three years from initial diagnosis of DIPG
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Lucie Lafay-Cousin, MD, University of Calgary
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 15, 2017
Primary Completion (Estimated)
December 1, 2023
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
April 19, 2017
First Submitted That Met QC Criteria
April 19, 2017
First Posted (Actual)
April 24, 2017
Study Record Updates
Last Update Posted (Actual)
August 2, 2023
Last Update Submitted That Met QC Criteria
July 31, 2023
Last Verified
July 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Brain Stem Neoplasms
- Infratentorial Neoplasms
- Recurrence
- Glioma
- Diffuse Intrinsic Pontine Glioma
Other Study ID Numbers
- HREBA.CC16-0143
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent or Progressive Diffuse Intrinsic Pontine Glioma
-
National Cancer Institute (NCI)RecruitingRecurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...United States, Canada
-
University of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS); The Chad-Tough... and other collaboratorsRecruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent WHO Grade III Glioma | WHO Grade III GliomaUnited States, Israel, Australia, Netherlands, Switzerland, New Zealand
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedMalignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Atypical Teratoid/Rhabdoid Tumor | Refractory Diffuse Intrinsic Pontine Glioma | CNS Embryonal Tumor, Not Otherwise SpecifiedUnited States
-
Ralph NULL SalloumChildren's Hospital Medical Center, CincinnatiRecruitingHigh Grade Glioma | Medulloblastoma | Meningioma | Anaplastic Ependymoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary... and other conditionsUnited States
-
University of CincinnatiChildren's Hospital Medical Center, CincinnatiCompletedRecurrent Diffuse Intrinsic Pontine GliomaUnited States
-
Shenzhen Geno-Immune Medical InstituteShenzhen Children's Hospital; Shenzhen Hospital of Southern Medical UniversityUnknownDiffuse Intrinsic Pontine Glioma or GlioblastomaChina
-
National Cancer Institute (NCI)RecruitingLynch Syndrome | Malignant Glioma | Recurrent Childhood Ependymoma | Recurrent Medulloblastoma | Refractory Ependymoma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Refractory Diffuse Intrinsic Pontine Glioma | Recurrent Brain Neoplasm | Refractory Brain Neoplasm | Constitutional...United States, Canada
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Solving Kids' CancerCompletedDiffuse Intrinsic Pontine Glioma (DIPG)United States
-
YM BioSciencesCompletedRecurrent Diffuse Pontine GliomasUnited States, Canada, Israel
-
University of FloridaAccelerate Brain Cancer Cure; Lyla Nsouli FoundationActive, not recruitingBrain Stem Glioma | Diffuse Intrinsic Pontine Glioma (DIPG)United States
Clinical Trials on re-irradiation
-
University Hospital HeidelbergRecruitingLocally Advanced Head-and-Neck CancerGermany
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Medical College of WisconsinRecruiting
-
Rigshospitalet, DenmarkKarolinska University Hospital; Aarhus University Hospital; Sahlgrenska University... and other collaboratorsNot yet recruitingDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Diffuse Glioma | Pontine Tumors | Brain Tumor, Pediatric | Thalamic Tumor
-
Changhai HospitalActive, not recruitingPancreatic CancerChina
-
Istituto Scientifico Romagnolo per lo Studio e...Recruiting
-
Hadassah Medical OrganizationCompletedPediatric Malignant Brain Tumor -Diffuse Intrinsic Pontine GliomaIsrael
-
University College, LondonGlaxoSmithKlineWithdrawnRecurrent Glioblastoma
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Ege UniversityNot yet recruiting